Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.55 |
| ▸ | NPY1R | P25929 | 7/20 | 0.55 |
| ▸ | NPY2R | P49146 | 5/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074747 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL9419221 | 1.00 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL13449160 | 0.97 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29797028 | 0.96 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30082669 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30998029 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL7594012 | 0.92 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL7594031 | 0.92 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL29531971 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL30903436 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | claimed |
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-28 | — | — | US | disclosed |
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-5354675-A | Amidation of glycine | SHISEIDO COMPANY LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0447547-B1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO CO LTD (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0447547-A1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO COMPANY LIMITED (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | NPY4R 15/4885NPY1R 19/4885NPY2R 27/4885 |
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | MC4R, MC3R, MC5R | NPY4R 6/4885NPY1R 9/4885NPY2R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.